MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.43
+0.18
+1.11%
After Hours: 16.19 -0.24 -1.46% 17:44 08/07 EDT
OPEN
16.38
PREV CLOSE
16.25
HIGH
17.00
LOW
15.48
VOLUME
37.84K
TURNOVER
--
52 WEEK HIGH
28.85
52 WEEK LOW
14.14
MARKET CAP
180.97M
P/E (TTM)
-14.8876
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XOMA stock price target is 29.50 with a high estimate of 30.00 and a low estimate of 29.00.

EPS

XOMA News

More
XOMA EPS beats by $0.05, misses on revenue
XOMA (NASDAQ:XOMA): Q2 GAAP EPS of -$0.33 beats by $0.05. Revenue of $0.44M (-54.2% Y/Y) misses by $1.82M. Press Release
seekingalpha · 21h ago
Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 23h ago
XOMA Reports Second Quarter 2020 Financial Results
Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impactsEMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its second quarter 202
GlobeNewswire · 1d ago
XOMA to Present at the 2020 Wedbush PacGrow Healthcare Conference
Live video feed will be available on XOMA’s websiteEMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present a Company business update at the Wedbush PacGrow Virtua
GlobeNewswire · 2d ago
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Natural Gas Ready To Double: The Best Ways To Play It
Seeking Alpha · 07/27 14:15
XOMA Announces Natasha Hernday Joins its Board of Directors
XOMA Corporation (XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, Inc., has joined the Company’s Board of Directors. Ms. Hernday has 20 years of experience in corporate development and corporate stra
GlobeNewswire · 07/01 11:30
XOMA Added To Russell 2000 And Russell 3000 Indexes
Benzinga · 06/29 11:39

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Symbol
Price
%Change

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
More

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.